AstraZeneca SVP Sharma Mani Buys 21.233 Shares

What Happened Sharma Mani, SVP, Group Controller and Head of Global Finance Services at AstraZeneca (AZN), reported two acquisitions: an open-market/private purchase of 20.233 shares on 2026-08-08 at $160.57 per share (total $3,249) and receipt of a 1-share award on 2026-09-08 valued at $162.60 (total $163). Both transactions are acquisitions (purchase + award), which are purchases rather than sales.

Key Details

• Transactions:
  • 2026-08-08 — Purchase (code P): 20.233 shares at $160.57 each; total $3,249.
  • 2026-09-08 — Award/Grant (code A): 1 share at $162.60; total $163.
• Combined shares acquired: 21.233 shares; combined reported value ≈ $3,412.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Aug 8 activity involves automatic reinvestment of dividend-equivalent units under the Issuer's Restricted Share Plan at GBP118.96 converted to USD using GBP1 = $1.3498 (Aug 7, 2026). Those dividend units vest and will be released after a three-year holding period.
  • F2: The Sep 8 acquisition was under the Issuer's Share Incentive Plan at GBP120.26 converted using GBP1 = $1.3521 (Sep 4, 2026).
• Filing timeliness: The Form 4 was filed on 2026-09-11. Because the Aug 8 purchase occurred more than two business days before the filing date, that transaction appears to have been reported late.

Context

• Codes: P = purchase (open market/private), A = award/grant. These were acquisitions, not sales.
• Awards and plan-related reinvestments (like F1/F2) often reflect company compensation plan mechanics rather than active market timing; they do increase insider ownership but are not direct market-timing signals.
• No indication in the filing of a cashless exercise, gift, or tax-withholding sale.